PI
CLDX icon

Putnam Investments’s Celldex Therapeutics CLDX Stock Holding History

Putnam Investments’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-4,735
Closed -$1.11M – 1413
2015
Q4 		$1.11M Sell
4,735
-80
-2% -$17.4K ﹤0.01% 1134
2015
Q3 		$761K Buy
+4,815
New +$1.36M ﹤0.01% 1232
2014
Q3 		– Sell
-1,836
Closed -$449K – 1504
2014
Q2 		$449K Buy
1,836
+2
+0.1% +$452 ﹤0.01% 1341
2014
Q1 		$486K Sell
1,834
-26,023
-93% -$9.96M ﹤0.01% 1360
2013
Q4 		$10.1M Sell
27,857
-20,108
-42% -$7.75M 0.02% 451
2013
Q3 		$25.5M Buy
47,965
+13,978
+41% +$4.79M 0.07% 275
2013
Q2 		$7.96M Buy
+33,987
New +$6.69M 0.02% 491

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Putnam Investments's CLDX Position: Q1 2016 in Review

Putnam Investments sold out of Celldex Therapeutics (CLDX) in Q1 2016, closing a stake of 4,735 shares — an estimated $1.11M sold.

Putnam Investments first reported a position in CLDX in Q2 2013 and held it in 7 quarters. The position peaked at $25.5M in Q3 2013. 145 funds tracked by Wall St. Rank hold CLDX as of Q1 2016.

  • Putnam Investments reported no remaining Celldex Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Putnam Investments sold 4,735 Celldex Therapeutics shares in Q1 2016, an estimated $1.11M.
  • Putnam Investments first reported a position in Celldex Therapeutics in Q2 2013 and held it in 7 quarters.
  • Putnam Investments's Celldex Therapeutics position peaked at $25.5M in Q3 2013.
  • 145 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2016.

Based on Putnam Investments's 13F filing for Q1 2016, filed 16 May 2016.